{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for nonoxynol root_references_@count in root_references_@count (approximate match)
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT00141180: Phase 1 Interventional Completed Dermatitis, Allergic Contact
(2003)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00045786: Phase 2 Interventional Completed Myelodysplastic Syndrome
(2001)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Class (Stereo):
CHEMICAL (RACEMIC)
Oxapropanium was studied as a cholinergic agent. Information about the current use of this compound is not available.
Status:
Investigational
Source:
JAN:BEPERIDIUM IODIDE [JAN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Beperidium (also known as SX-810 ) is a competitive antagonist against acetylcholine. Experiments on animal have shown that this compound exhibited spasmolytic and antiulcerative activities without exerting systemic antimuscarinic side effects.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Datelliptium is a DNA-intercalating agent, an analog of a natural alkaloid ellipticine. The compound was active in vivo against a variety of murine solid tumors. In a phase I clinical trial no objective complete or partial responses were observed in patients with solid tumors or lymphoma treated with datelliptium.
Status:
Class (Stereo):
CHEMICAL (MIXED)
Cyclopyrronium bromide is an anticholinergic agent, discovered by Robins Company, Inc. Ex vivo study has demonstrated that the compound was effective in inhibiting gastrointestinal motility in isolated guinea pig ileum.
Status:
Investigational
Source:
NCT02018250: Phase 1 Interventional Completed Safety and Efficacy
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Status:
Investigational
Source:
NCT00337415: Phase 2 Interventional Terminated Dyslipidemia
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
MK-0354 is a GPR109a (Niacin receptor 1) agonist, originated by Arena Pharmaceuticals. In phase II of clinical trials against dyslipidemia treatment with MK-0354 failed to produce changes in high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or triglycerides.
Status:
Investigational
Source:
NCT03283059: Phase 3 Interventional Unknown status Alzheimer Disease
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
